[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.207.116. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Observation
April 2011

Kinesigenic Dyskinesia in a Case of Voltage-Gated Potassium Channel–Complex Protein Antibody Encephalitis

Author Affiliations

Author Affiliations: Department of Neurology, Drexel University College of Medicine, Philadelphia, Pennsylvania.

Arch Neurol. 2011;68(4):529-532. doi:10.1001/archneurol.2010.317

To our knowledge, this is the first description of a patient who had central neurologic signs of seizures, encephalopathy, and kinesigenic dystonia as well as fasciculations and peripheral cramps.

REPORT OF A CASE

A 38-year-old man presented with the chief complaint of the sudden onset of “stiffness” of both arms and legs. The problem had begun 8 weeks earlier, when the patient experienced 2 episodes of extreme anxiety that lasted for approximately 30 seconds with no associated loss of consciousness or abnormal movements. A few days after these 2 episodes, he noted the onset of abnormal movements, which were initiated by change of position or startle and would involve either the upper or the lower extremities. The movements occurred up to 40 to 50 times per day and were exacerbated by stress and lack of sleep. The patient subsequently developed clear cognitive decline manifested as difficulty with short-term memory and concentration. The episodes of anxiety increased in frequency and intensity and were followed by 2 witnessed generalized tonic-clonic seizures. The patient was admitted to an outlying hospital and underwent an extensive workup, which included routine magnetic resonance imaging without gadolinium, cerebral arteriography, and routine blood, urine, and cerebrospinal fluid analysis, the results of which were normal. He also had bronchial asthma, eczema, vitiligo, and immune complex mesangiopathic glomerulonephritis. He was taking 500 mg of mycophenolate mofetil (CellCept [2-morpholino-ethyl ester of mycophenolic acid]) twice a day for his renal condition.

On admission, he was fully alert and oriented but had trouble with immediate recall and tasks that required concentration (eg, serial 7s). He had slight forward flexed posture but otherwise had full strength, sensation, and coordination. He demonstrated multiple episodes of kinesigenic dyskinesia, which were always initiated by sudden movement (most often by reaching for objects or attempting to get up from a sitting position). The movements were at times bilateral and at times unilateral. He would flex at the elbow and wrist and extend his knees while dorsiflexing his foot. His face involved the orbicularis oculi, buccinator muscles, and lower facial musculature. The episodes were stereotyped and lasted 3 to 10 seconds (video). He had full recollection of the events and had no loss of consciousness or confusion. He had 20 to 30 episodes per hour. He also demonstrated fasciculations at rest, most prominently of the quadriceps and gastrocnemius muscles.

Magnetic resonance imaging of the brain with gadolinium revealed increased fluid-attenuated inverse recovery signal of the head of the left caudate and the middle of the left putamen (Figure 1). The lesions enhanced with gadolinium (Figure 1C). Single-photon emission computed tomography demonstrated increased uptake in similar regions (Figure 2). Autoantibody and paraneoplastic evaluation revealed an elevated voltage-gated potassium channel (VGKC) antibody titer (0.97 nmol/L; reference value, <0.02 nmol/L) and an elevated ganglionic acetylcholine receptor antibody titer (0.45 nmol/L; reference value, 0.02 nmol/L). Electromyography and nerve conduction studies using the cramp-fasciculation protocol revealed significant afterdischarges with 3-Hz stimulation, significant cramp potentials with 5-Hz stimulation, and continuous motor activity with 10-Hz stimulation (Figure 3). The serum sodium level on admission was 128 mEq/L (to convert to millimoles per liter, multiply by 1.0). A 72-hour continuous video-electroencephalographic monitoring system revealed nonspecific slowing but no epileptiform activity. The results of a complete malignancy workup, including total-body positron emission tomography, were negative.

Figure 1.
Magnetic resonance images of the brain. Fluid-attenuated inverse recovery (FLAIR) sequence (A, axial; B, coronal), gadolinium (gad)-enhanced T1-weighted images (C), and T2-weighted images (D), all demonstrating increased signal intensity in the left caudate and putamen (arrows).

Magnetic resonance images of the brain. Fluid-attenuated inverse recovery (FLAIR) sequence (A, axial; B, coronal), gadolinium (gad)-enhanced T1-weighted images (C), and T2-weighted images (D), all demonstrating increased signal intensity in the left caudate and putamen (arrows).

Figure 2.
Single-photon emission computed tomographic scans of the brain demonstrating increased flow in the left striatum region (arrows).

Single-photon emission computed tomographic scans of the brain demonstrating increased flow in the left striatum region (arrows).

Figure 3.
Electromyography and nerve conduction studies demonstrating cramp potentials (left) and continuous motor unit activity (right) during tibial repetitive nerve stimulation at 5 Hz and 10 Hz, respectively.

Electromyography and nerve conduction studies demonstrating cramp potentials (left) and continuous motor unit activity (right) during tibial repetitive nerve stimulation at 5 Hz and 10 Hz, respectively.

Levetiracetam therapy (1000 mg twice a day) was initiated and was continued throughout the course of the patient's evaluation. The patient underwent 5 plasma exchanges during the first week. There was no clinical improvement. The second week, 5 intravenous immunoglobulin infusions of 2 mg/kg were administered over 4 to 5 hours with 30 mg of prednisone. On the 10th day (third intravenous immunoglobulin infusion), the kinesigenic dyskinesia decreased dramatically to only 1 to 2 very mild episodes per day. The patient no longer had spontaneous fasciculations. Topiramate (100 mg every night) was added to his regimen the last week of treatment. At the 8-week follow-up visit, his VGKC antibody level was undetectable.

COMMENT

To our knowledge, this is the first reported case involving both VGKC complex protein antibody encephalitis and fasciculations associated with kinesigenic dyskinesia. Because of the patient's history of 2 autoimmune diseases—vitiligo and immune complex mesangiopathic glomerulonephritis—and negative cancer evaluation findings, we believed that the VGKC encephalitis and the peripheral cramp-fasciculation syndrome were on an autoimmune basis. He had the typical clinical presentation for the VGKC antibody spectrum disease, including seizures and memory and cognitive impairment, supported by the laboratory findings of a slow electroencephalogram, hyponatremia, and an elevated antibody titer. Two other patients have been described with caudate and putaminal lesions associated with this syndrome.1,2 Two clinically similar cases have also been reported,3,4 but, unlike our patient, both patients had clear electroencephalographic abnormalities, and neither had basal ganglia lesions on magnetic resonance images. Our patient is unique in that he developed kinesigenic dyskinesia and asymptomatic cramp-fasciculation syndrome. Also, he did not complain of any of the typical symptoms of peripheral nerve hyperexcitability that have been described in association with VGKC antibody spectrum diseases (neuromyotonia or Isaacs syndrome, cramp-fasciculation syndrome, and Morvan syndrome).59 He did, however, have prominent fasciculations, especially in the lower extremities.

Until recently, VGKCs were thought to be the antigenic target in these patients.8,9 The work by Lai et al10 and Irani et al11 has demonstrated that the antigenic targets are proteins that form a complex with these VGKCs, ie, leucine-rich glioma-inactivated 1 and contactin-associated protein 2. Leucine-rich glioma-inactivated 1 associates with the VGKC KV1.1, and, clinically, patients who had this antibody had more central nervous system manifestations (limbic encephalitis, seizures, and altered mental status). Contactin-associated protein 2 associates with both KV1.1 and KV1.2 VGKCs at the neural juxtaparanodal region, and patients with contactin-associated protein 2 antibodies present clinically with fewer nervous system symptoms and more features of peripheral nervous system dysfunction. Of note, none of the patients described in these 2 articles had dyskinesia or evidence of basal ganglia lesions on magnetic resonance images. Although the exact mechanism is unknown, it is probable that these antibodies cause dysfunction of the VGKCs and increase their excitability. In our patient, this hyperexcitability of VGKC may have led to the loss of inhibition of the globus pallidus, with consequent disinhibition of the motor thalamus. The specific VGKCs (KV1.1 and KV1.2) are known to be hyperpolarizing to neurons of the striatum and may have been affected in this case.1214

Kinesigenic dyskinesia may include dystonia, ballism, chorea, or athetosis. It is induced by sudden voluntary movement and may occur (secondary form) as a result of a wide variety of conditions, including trauma, metabolic abnormalities, multiple sclerosis, kernicterus, and central nervous system infections.1517 The literature supports treatment of this condition with a variety of immunosuppressive strategies.5,6,8,9,1719 Our patient was treated with plasmapheresis, intravenous immunoglobulin, and anticonvulsant agents. We are not sure which of the modalities that were used were effective in his treatment.

Back to top
Article Information

Correspondence: Robert J. Schwartzman, MD, Department of Neurology, Drexel University College of Medicine, 245 N 15th St, MS 423, Philadelphia, PA 19102-1192 (Robert.Schwartzman@drexelmed.edu).

Accepted for Publication: September 28, 2010.

Published Online: December 13, 2010. doi:10.1001/archneurol.2010.317

Author Contributions:Study concept and design: Aradillas and Schwartzman. Acquisition of data: Aradillas. Analysis and interpretation of data: Aradillas and Schwartzman. Drafting of the manuscript: Aradillas. Critical revision of the manuscript for important intellectual content: Schwartzman. Administrative, technical, and material support: Aradillas. Study supervision: Schwartzman.

Financial Disclosure: None reported.

References
1.
Irani  SRBuckley  CVincent  A  et al.  Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008;71 (20) 1647- 1648
PubMedArticle
2.
Hiraga  AKuwabara  SHayakawa  S  et al.  Voltage-gated potassium channel antibody-associated encephalitis with basal ganglia lesions. Neurology 2006;66 (11) 1780- 1781
PubMedArticle
3.
Toosy  ATBurbridge  SEPitkanen  M  et al.  Functional imaging correlates of fronto-temporal dysfunction in Morvan's syndrome. J Neurol Neurosurg Psychiatry 2008;79 (6) 734- 735
PubMedArticle
4.
Barajas  RFCollins  DECha  SGeschwind  MD Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 2010;51 (3) 473- 477
PubMedArticle
5.
Thieben  MJLennon  VABoeve  BFAksamit  AJKeegan  MVernino  S Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62 (7) 1177- 1182
PubMedArticle
6.
Reid  JMFoley  PWillison  HJ Voltage-gated potassium channel-associated limbic encephalitis in the West of Scotland: case reports and literature review. Scott Med J 2009;54 (4) 27- 31
PubMedArticle
7.
Dalmau  JRosenfeld  MR Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7 (4) 327- 340
PubMedArticle
8.
Vincent  ABuckley  CSchott  JM  et al.  Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127 (Pt 3) 701- 712
PubMedArticle
9.
Tan  KMLennon  VAKlein  CJBoeve  BFPittock  SJ Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70 (20) 1883- 1890
PubMedArticle
10.
Lai  MHuijbers  MGLancaster  E  et al.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9 (8) 776- 785
PubMedArticle
11.
Irani  SRAlexander  SWaters  P  et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133 (9) 2734- 2748
PubMedArticle
12.
Demirkiran  MJankovic  J Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995;38 (4) 571- 579
PubMedArticle
13.
Wulff  HCastle  NAPardo  LA Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 2009;8 (12) 982- 1001
PubMedArticle
14.
Vernino  S Autoimmune and paraneoplastic channelopathies. Neurotherapeutics 2007;4 (2) 305- 314
PubMedArticle
15.
Blakeley  JJankovic  J Secondary paroxysmal dyskinesias. Mov Disord 2002;17 (4) 726- 734
PubMedArticle
16.
Lotze  TJankovic  J Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003;10 (1) 68- 79
PubMedArticle
17.
van Rootselaar  AFvan Westrum  SSVelis  DNTijssen  MA The paroxysmal dyskinesias. Pract Neurol 2009;9 (2) 102- 109
PubMedArticle
18.
Mittal  MHammond  NG Lynch  S Immunotherapy responsive autoimmune subacute encephalitis: a report of two cases. Case Report Med 2010;2010837371
PubMed
19.
Ohshita  TKawakami  HMaruyama  HKohriyama  TArimura  KMatsumoto  M Voltage-gated potassium channel antibodies associated limbic encephalitis in a patient with invasive thymoma. J Neurol Sci 2006;250 (1-2) 167- 169
PubMedArticle
×